Intensity Therapeutics is a clinical-stage biotechnology company engaged in developing anti-cancer immune activation. Co.'s proprietary technology platform, DfuseRxSM involves the direct injection into tumors and diffuse therapeutic agents into cancer cells. Co.'s lead product candidate, INT230-6 consists of two anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed in water with the amphiphilic molecule (SHAO) is used for sarcoma, breast and also lung cancer. We show 3 historical shares outstanding datapoints in our INTS shares outstanding history coverage, used to compute INTS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing INTS market cap history over the course of time is important for investors
interested in comparing INTS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of INTS versus a peer is one thing; comparing
INTS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like INTS can fluctuate over the course of history.
With this page we aim to empower investors researching INTS by allowing them to research the INTS market cap history. |
Free INTS Email Alerts:
Video: The Importance of Market Cap
